clinical trials
clinical trials
Dragonfly Research, The Elliot Lewis Center’s research arm, is currently conducting many clinical trials for relapsing and progressive forms of multiple sclerosis. Ongoing research includes phase II and phase III clinical trials, as well as phase IV observational trials, investigating the efficacy of new and existing multiple sclerosis therapies.
Opportunities to enroll for studies at Dragonfly Research change regularly, and enrollment is limited. If you are interested in participating, we encourage you to contact us as soon as possible and check this page frequently. Our Clinical Research Coordinators can be reached at 781-591-8313.
The Elliot Lewis Center and Dragonfly Research also conduct independent research projects to address important clinical issues. Learn more here.
Acapella
Clinical Trial Opportunity for Patients with Multiple Sclerosis
The Acapella study was started after the first commercial Ocrevus infusion was delivered at our site. The Acapella study is a real world, prospective, observational study evaluating the safety of Ocrevus in patients with relapsing and progressive multiple sclerosis. The Elliot Lewis Center currently has 6 years of Acapella data with a focus on patient infection and malignancy rates and immunoglobulin levels.
Corevitas MS Registry Study
Clinical Trial Opportunity for Patients with Multiple Sclerosis
The Corevitas MS Registry Study is the largest observational study at the Elliot Lewis Center, designed as a prospective, non-interventional research study for MS patients currently taking a disease modifying therapy or planning to initiate treatment. The primary objective of this registry is to study the natural history of MS, the prevalence and incidence of comorbidities and targeted adverse events, and the comparative effectiveness and safety of approved MS treatments. Subjects provide patient reported outcomes via questionnaires at office visits that are evaluated alongside physician reported outcomes. An option MRI registry study has been added to the main registry to collect more in-depth data on patient MRI activity
Fentrepid
Clinical Trial Opportunity for Patients with Primary Progressive Multiple Sclerosis
Fentrepid is a clinical trial for participants with primary progressive multiple sclerosis (PPMS) between the ages of 18-65. The study drug fenebrutinib is a BTK inhibitor (BTK-I) which penetrates the central nervous system and impacts the immune system. Patients are randomized to receive either active fenebrutinib and placebo or active ocrelizumab and placebo in this double-blind, double-dummy study. Because fenebrutinib is given as a pill and ocrelizumab is administered into the vein using a needle (an infusion), patients receive both pills and infusions, so study medication is unknown during the 2.3-year double-blind phase. Upon successful completion of the blinded phase, patients have the option to receive open-label fenebrutinib for 1.8 years.
Not currently enrolling.
EMD Aging Study
Clinical Trial Opportunity for Patients with Relapsing Multiple Sclerosis
The EMD Aging study is an observational trial characterizing the clinical course in a real-world, US Cohort of patients with relapsing multiple sclerosis at least 50 years of age treated with cladribine. Retrospective analysis is done to gather data on the efficacy of cladribine and treatment course.
MUSETTE
Clinical Trial Opportunity for Patients with Relapsing Remitting Multiple Sclerosis
MUSETTE is a clinical trial for patients with Relapsing MS aged 18-55. Patients will receive Ocrevus for 4.5 years through the study. To be eligible patients must have at least one documented relapse in the past year, and must ambulate without assistance. Patients must NOT have received previous treatment with Ocrevus or Rituxan in the past two years.
In addition to collecting safety data, the study is evaluating the efficacy and safety of higher dose Ocrevus in adults with RMS.
The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
Not currently enrolling.
GAVOTTE
Clinical Trial Opportunity for Patients with Primary Progressive Multiple Sclerosis
GAVOTTE is a clinical trial for patients with Primary Progressive MS aged 18-55. Patients will receive Ocrevus for 4.5 years through the study. To be eligible patients can use a cane or a walker, but not a wheelchair. Patients must NOT have received previous treatment with Ocrevus or Rituxan in the past two years.
In addition to collecting safety data, the study is evaluating the efficacy and safety of higher dose Ocrevus in adults with PPMS.
The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
Not currently enrolling
EXCHANGE
Clinical Trial Opportunity for Patients with Relapsing & Secondary Progressive MS
Patients aged 18-65 with Relapsing or Secondary Progressive MS may be eligible for treatment with Siponimod, an investigational MS therapy.
This study is tracking the tolerability of Siponimod and any potential immune effects. Siponimod is a once-daily pill and patients will receive 6 months of treatment through the study. After completing the study, patients will have the option to receive Siponimod through a managed access program until it becomes commercially available.
Patients must currently be treated with any oral or injectable MS therapy. Certain previous MS therapies may be exclusionary. The study requires 4 visits over the course of 6 months and does not require any MRIs. The medication, assessments, and physician appointments are covered by the study.
Not currently enrolling
CONSONANCE
Clinical Trial Opportunity for Patients with Primary Progressive & Secondary Progressive MS
CONSONANCE is a clinical trial for patients with Primary and Secondary Progressive MS aged 18-65. Patients will receive Ocrevus for four years through the study. To be eligible patients can use a cane or a walker, but not a wheelchair. Patients must NOT have received previous treatment with Ocrevus or Rituxan.
In addition to collecting safety data, the study is investigating the use of smartphones to track patient symptoms. 75% of patients who enter the trial will receive a smartphone with daily and weekly tasks, tracking day-to-day symptoms.
The study requires MRIs every 6 months for the first year and then yearly following. The Ocrevus, MRIs, assessments, and physician appointments are all covered by the study.
Not currently enrolling
Contact our Clinical Research Coordinators at 781-591-8313 for more information.